Opinion|Videos|June 26, 2024
Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Looking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Looking to the future of Alzheimer disease treatment, what are your key takeaways on the evolving therapeutic landscape?
Advertisement
Related to this article
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5